Successful Treatment with Imatinib Mesylate of a CML Patient in Megakaryoblastic Crisis with Severe Fibrosis
- 40 Downloads
The prognosis of patients with chronic myeloid leukemia in blastic crisis (CML-BC) remains extremely poor, and multiagent chemotherapy regimens commonly used to treat acute leukemia offer only short-term benefits. Therefore, the advent of the novel molecularly targeted anticancer agent imatinib mesylate is a breakthrough in CML therapy. We present a CML patient in megakaryoblastic crisis with severe myelofibrosis, who was treated with imatinib at a dosage of 400 mg/day and achieved complete remission together with a marked regression of myelofibrosis after 1 month. The effect of imatinib on the long-term prognosis remains unclear, although the agent is clearly a promising drug for treating CML-BC even in cases of myelofibrosis.Int J Hematol. 2002; 76: 349-353.
Key wordsChronic myeloid leukemia Blastic crisis Myelofibrosis Imatinib mesylate Molecular targeted therapy
Unable to display preview. Download preview PDF.
- 3.Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists’ Collaborative Group.J Natl Cancer Inst. 1997; 89: 1616-1620.Google Scholar
- 10.Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.Cancer Res. 1996; 56: 100–104.Google Scholar
- 22.Bauermeister DE. Quantification of bone marrow reticulin: a normal range.Am J Clin Pathol. 1971; 72: 68–70.Google Scholar